Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

NCT03093415 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C
Substance Use Disorders
Substance Abuse, Intravenous

Interventions

DRUG: elbasvir-grazoprevir (50 mg/100 mg)

Sponsor

Oregon Health and Science University